Phospholipid inhibitors: State of the art

Hamostaseologie

Volumn 31, Issue 4, 2011, Pages 243-250

  Galli, M ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Abortion; Antiphospholipid antibodies; Antiphospholipid syndrome; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; FEMALE; FETUS WASTAGE; HUMAN; INNATE IMMUNITY; INTERNATIONAL NORMALIZED RATIO; PATHOGENESIS; PREGNANCY COMPLICATION; PREGNANT WOMAN; PROGNOSIS; REVIEW; TREATMENT DURATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PHOSPHOLIPIDS; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 83755225857     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1165     Document Type: Review

References (69)

1. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295-306.
2. Pengo V, Tripodi A, Reber G et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-1740.
3. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027.
4. Cervera R, Khamashta MA, Shoenfeld Y et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68: 1428-1432.
5. Cervera R on behalf of the 'CAPS Registry'. Catastrophic Antiphospholipid Syndrome (CAPS). Lupus 2010; 19: 412-418.
6. Piette JC, Cervera R, Levy R et al. The catastrophic antiphospholipid syndrome -Asherson's syndrome. Ann Med Intern 2003; 154: 95-96.
7. Tincani A, Filippini M, Scarsi M et al. European attempts for the standardisation of the antiphos -pholipid antibodies. Lupus 2009; 18: 913-919.
8. Tincani A, Allegri F, Balestrieri G et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553-558.
9. Wong RCW, Gillis D, Adelstein S et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology 2004; 36: 63-68.
10. Reber G, Shousboe I, Ticani A et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. Thromb Haemost 2002; 88; 66-73.
11. Reber G, Tincani A, Sanmarco M et al. Variability of anti-beta2-gycoprotein I antibodies measurement by commercial assays. Thromb Haemost 2005; 94: 665-672.
12. Reber G, Tincani A, Sanmarco M et al. Proposal for the measurement of anti-beta2-gycoprotein I antibodies. Standardization group of the European Forum on antiphospholipid antibodies. J Thromb Haemost 2004; 2: 1860-1862.
13. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.
14. Galli M, Comfurius P, Maassen C et al. Anticardio -lipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 334: 1544-1547.
15. Matsuura E, Igarashi Y, Fujimoto M et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-178.
16. De Laat BH, Derksen RHWM, van Lummel M et al. Pathogenic anti-β2-glycoprotein I antibodies recognize β2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916-1924.
17. De Laat BH, Derksen RHWM, Ubanus RT et al. β2GPI-dependent lupus anticoagulant activity highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598-3602.
18. De Laat BH, Derksen RHWM, Ubanus RT et al. IgG antibodies that recognize the epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-1545.
19. Galli M. The antiphospholipid triangle. J Thromb Haemost 2010; 8: 234-236.
20. Simmelink MJ, Derksen RHW, Arnout J, de Groot P. A simple method to discriminate between β2GPIdependent-and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003; 1: 740-747.
21. Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A twostep coagulation test to identify anti-β2-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 2: 702-707.
22. Devreese K. A functional coagulation test to identify anti-β2-glycoprotein I-dependent lupus anticoagulants. Thromb Res 2007; 119: 753-759.
23. Galli M, Beretta G, Daldossi M et al. Different anticoagulant and immunological properties of antiprothrombin antibodies in patients with antiphospholipid antiobides. Thromb Haemost 1997; 77: 486-491.
24. Bevers EM, Galli M, Barbui T et al. Lupus anticoagulant IgG's are not directed to phospholipids only but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-632.
25. Horbach DA, van Oort E, Derksen RHWM, de Groot P. The contribution of anti-prothrombinantibodies to lupus anticoagulant activity--discrimination between functional and non-functional anti-prothrombin-antibodies. Thromb Haemost 1998; 79: 790-795.
26. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.
27. Galli M, Luciani D, Bertolini G, Barbui T. Antiβ2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-2723.
28. Opatrny L, David M, Khan SR et al. Association between antiphospholipid antibodies and recurrent fetal loss in omen without autoimmune diseases: a metaanalysis. J Rheumatol 2006; 33: 2214-2221.
29. Previtali S, Barbui T, Galli M. Anti-β2-glycoprotein I and antiprothrombin antibodies in antiphos -pholipid-negative patients with thrombosis. A casecontrol study. Thromb Haemost 2002; 88: 729-732.
30. Pengo V, Biasiolo A, Pegoraro C et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-1152.
31. Ruffatti A, Tonello M, Del Ross T et al. Antibody profile and clinical course in primary antiphos -pholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96: 337-341.
32. Pengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients diagnosed with antiphos -pholipid sindrome. J Thromb Haemost 2010; 8: 237-242.
33. Lee EY, Chang-Keun L, Lee TH et al. Does the anti-β2-glycoprotein I antibody provide additional information in patients with thrombosis? Thromb Res 2003; 111: 29-32.
34. Male C, Foulon D, Hogendoorn H et al. Predictive values of persistent versus transient antiphospho -lipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106: 4152-4158.
35. Forastiero R, Martinuzzo M, Pombo G et al. A prospective study of antibodies to β2-GPI and prothrombin and risk of thrombosis. J Thromb Haemost 2005; 3: 1231-1238.
36. De Laat B, Pengo V, Pabinger I. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-7173.
37. Reverter JC, Tassies D, Font J et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free proteins. Arterioscler Thromb Vasc Biol 1996; 16: 1319-1326.
38. Wu XX, Pierangeli SS, Rand JH. Resistance to annexin A5 binding and anticoagulant activity in the plasma of patients with the antiphospholipid syndrome but not with syphilis. J Thromb Haemost 2006; 4: 271-273.
39. Devreese K, Peerlinck K, Arnout J, Hoylaerts FS. Laboratory detection of antiphospholipid syndrome via automated thrombography. Thromb Haemost 2009; 101: 185-196.
40. Pierangeli SS, Colden-Stanfiled M, Liu X et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activated endothelial cells in vitro and in vivo. Circulation 1999; 99: 19997-2002.
41. Lopez-Pedrera C, Buendia P, Cuadrado MJ et al. Antiphospholipid antibodies from patients with the antiphospholipid sindrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappa B/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54: 301-311.
42. Shi T, Giannakopoulos B, Yan X et al. Antibeta2-glycoprotein I in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54: 2558-2567.
43. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88: 3069-3073.
44. Pierangeli SS, Barker JH, Stikovac D et al. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost 1994; 71; 670-674.
45. Robertson SA, Roberts CT, van Beijering E et al. Effect of beta2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibodymediated pregnancy pathology in mice. Mol Hum Reprod 2004; 10: 409-416.
46. Ramesh S, Morrell CN, Tarango C et al. Antiphos -pholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via ß2GPI and apoER2. J Clin Invest 2011; 121: 120-131.
47. Shoenfeld Y. Induction of experimental primary and secondary antiphospholipid syndromes in naive mice. Am J Reprod Immunol 1992; 28: 219-222.
48. Gharavi AE, Aron AL. Experimental models for antiphospholipid studies. Haemostasis 1994; 24: 204-207.
49. Bevers EM, Jannsen MP, Comfurius P et al. Quantitative determination of the binding of beta2-glycoprotein I and prothrombin to phosphatidylserineexposing blood platelets. Biochem J 2005; 386: 271-279.
50. Gushiken FC, Le A, Arnett FC, Thiagarajan P. Polymorphisms beta2-glycoprotein I: phospholipids binding and multimeric structure. Thromb Res 2002; 108: 175-180.
51. Cline AM, Radic MZ. Apoptosis, subcellular particles, and autoimmunity. Clin Immunol 2004; 112: 175-182.
52. Levine JS, Subang R, Koh JS, Rauch J. Induction of anti-phospholipid autoantibodies by beta2-glycoprotein I bound to apoptotic thymocytes. J Autoimmun 1998; 11: 413-424.
53. D'Agnillo P, Levine JS, Subang R, Rauch J. Prothrombin binds to the surface of apoptotic, but not viable, cells and serves as a target of lupus anticoagulant autoantibodies. J Immunol 2003; 170: 3408-3422.
54. Levine JS, Subang R, Koh JS, Nasr SH et al. Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J Immunol 2006; 177: 6504-6516.
55. Blank M, Krause I, Fridkin M et al. Bacterial induction of autoantibodies to beta2-glycoprotein I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109: 797-804.
56. Gharavi AE, Pierangeli SS, Colden-Stanfield M et al. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate cells in vivo and in vitro. J Autoimm 1999; 163: 2922-2927.
57. Rauch J, Dieudié M, Subang R, Levine JS. The dual role of innate immunity in the antiphospholipid syndrome. Lupus 2010; 19: 347-353.
58. Raschi E, Testoni C, Bosisio D et al. Role of the MyD88 transduction signalling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-3500.
59. Ioannou Y, Rahman A. Domain I of β2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome. Lupus 2010; 19: 400-405.
60. Ioannou Y, Romay-Penabad Z, Pericleous C et al. In-vivo inhibition of antiphospholipid antibody induced pathogenicity utilizing the antigenic target peptide domain I of β2-glycoprotein I: proof of concept. J Thromb Haemost 2099; 7: 833-842.
61. Finazzi G, Brancaccio V, Moia M et al. Natural history and risk for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-536.
62. Kearon C, Ginsberg JS, Kovacs MJ et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
63. Finazzi G, Marchioli R, Brancaccio V et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-853.
64. Crowther MA, Wisloff F. Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thromb Res 2005; 115: 3-8.
65. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295: 1050-1057.
66. Levine SR, Brey RL, Tilley BC et al. Antiphospho -lipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-584.
67. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57: 1487-1495.
68. Keeling D. Duration of anticoagulation: decision making based on absolute risk. Blood Rev 2006; 20: 173-178.
69. Laskin CA, Spitzer KA, Clark CA et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss; results from the randomized, controlled, HepASA Trial. J Rheumatol 2009; 36: 279-287.